- Home
- AXS vs PTGX Comparison
AXS vs PTGX Comparison
Compare AXS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | PTGX |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Bermuda | United States |
| Employees | 1966 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | AXS | PTGX |
|---|---|---|
| Price | $96.07 | $93.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $121.29 | $108.23 |
| AVG Volume (30 Days) | ★ 507.2K | 455.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $2.53 | $874.25 |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | ★ $8.43 | $1,898.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $88.07 | $49.86 |
| 52 Week High | $110.34 | $107.84 |
Technical Indicators
Market Signals| Indicator | AXS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 39.71 |
| Support Level | $94.12 | $90.58 |
| Resistance Level | $99.01 | $94.89 |
| Average True Range (ATR) | 2.28 | 4.03 |
| MACD | -0.40 | -0.56 |
| Stochastic Oscillator | 24.77 | 5.03 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.